{"url_path":"/sec/vstm/8-k/2026-06-17/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-074915-index.html","accession_number":"0001104659-26-074915","cik":"0001526119","ticker":"VSTM","issuer_name":"Verastem, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-074915-index.html","primary_entity_key":"0001526119","primary_entity_name":"Verastem, Inc."},"word_count":59,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure**\n\n** **\n\nOn June 17, 2026, Verastem, Inc. (the “Company”)\nissued a press release announcing positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with standard-of-care\nchemotherapy in first-line metastatic pancreatic ductal carcinoma (“mPDAC”).\n\n \n\nA copy of this press release is furnished hereto as Exhibit 99.1\nto this Current Report on Form 8-K."}